GlassScriptPhysician profile
Emily Lefkowitz
NPI 1588195895
$5,497.98
in general payments reported to CMS, 2019-2025
21 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $287 · 2021: $68.64 · 2022: $1,277 · 2023: $1,848 · 2024: $1,183 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.47 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,588.50 | 2019-2025 | |
| Janssen Biotech, INC. | $609.36 | 2022-2023 | Tremfya, Remicade, Stelara |
| Incyte Corporation | $531.63 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $491.91 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Genzyme Corporation | $337.29 | 2022-2025 | |
| Amgen INC. | $283.03 | 2020-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $273.03 | 2019-2024 | Dupixent |
| Pfizer INC. | $224.08 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $196.51 | 2022-2025 | Ilumya |
| Celgene Corporation | $178.66 | 2019 | |
| Ucb, INC. | $133.76 | 2022-2024 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $129.19 | 2022-2025 | Aklief, Oracea, Epsolay |
| Leo Pharma INC. | $117.66 | 2022 | |
| Dermavant Sciences, INC. | $112.41 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $85.33 | 2023-2024 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $57.22 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.57 | 2023-2024 | Cyltezo |
| Biofrontera INC. | $42.22 | 2022-2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Strata Skin Sciences, INC. | $21.83 | 2024 | Xtrac |
| Novartis Pharmaceuticals Corporation | $19.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Lefkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.